Global Genitourinary Drugs Market 2011-2015 Report Reveals That One of the Major Challenges Is the Increase in the Patent Expiries of the Best-Selling Drugs in the Market

DUBLIN, December 3, 2013 /PRNewswire/ --

Research and Markets ( http://www.researchandmarkets.com/research/67g6vc/global) has announced the addition of the "Global Genitourinary Drugs Market 2011-2015" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

TechNavio's analysts forecast the Global Genitourinary Drugs market to grow at a CAGR of 3.05 percent over the period 2011-2015. One of the key factors contributing to this market growth is the entry of novel biological drugs. The Global Genitourinary Drugs market has also been witnessing a paradigm shift toward biological drugs. However, lack of adherence to medication could pose a challenge to the growth of this market.

The key vendors dominating this space are Abbott Laboratories, Astellas Pharma Inc., Bayer AG, Eli Lilly and Co., GlaxoSmithKline plc, Merck and Co. Inc., and Pfizer Inc.

Other vendors mentioned in the report are Agile Therapeutics Inc., Allergan Inc., Antares Pharma Inc., Boehringer Ingelheim GmbH, Dong-A Pharmaceutical Co. Ltd., Detrol LA, Ferring Holding S.A., Kissei Pharmaceutical Co. Ltd., Merck Serono S.A., Novartis International AG, Novo Nordisk A/S, Nymox Pharmaceutical Corp., PregLem S.A., Recordati S.p.A., Rottapharm S.p.A., Teva Pharmaceutical Industries Ltd., VIVUS Inc., Warner Chilcott plc, and Watson Pharmaceuticals Inc.

Commenting on the report, an analyst from TechNavio's Healthcare team said: "Patients suffering from infections and disorders related to genitourinary systems are using steroids and immunosuppressants. However, these medications cause serious side effects because they are chemically synthesized. Hence, patients are turning to biological drugs that not only cause fewer side effects, but are also more effective in the treatment of genitourinary infection. Moreover, there has been an increase in the number of biological drugs entering the Global Genitourinary Drugs market."

According to the report, one of the major growth factors driving the Global Genitourinary Drugs market is the entry of novel drugs such as Cialis which are more effective than the drugs used in multiple-drug therapies. These novel drugs provide cost-effective treatment for genitourinary infection.


For more information visit http://www.researchandmarkets.com/research/67g6vc/global

Research and Markets
Laura Wood, Senior Manager.
[e-mail]
U.S. Fax: [phone]
Fax (outside U.S.): [phone]
Sector: Pharmaceuticals